Actinogen Medical Ltd. has announced the initiation of its XanaMIA phase 2b/3 clinical trial, aimed at assessing the efficacy of Xanamem, a novel oral treatment for Alzheimer's disease. This trial, now open at 20 sites across the United States, is recruiting participants diagnosed with mild to moderate Alzheimer's disease. The study examines the effects of Xanamem, which inhibits the production of cortisol in brain regions associated with memory and critical thinking, compared to a placebo over a 36-week period. Participants who complete this phase will be eligible for an open-label extension trial of Xanamem for up to 24 months, anticipated to commence in early 2026. No results from the trial have been presented yet, as participant recruitment and data collection are ongoing.